AIDS Alert Archives – January 1, 2003
January 1, 2003
View Archives Issues
-
New research confirms role of heart disease as a treatment by-product
While the exact cause remains to be found, it is no longer a mystery whether certain antiretroviral drugs can lead to metabolic changes associated with heart disease. -
AACTG recommendations for metabolic problems
The Adult AIDS Clinical Trials Group (AACTG) has responded to research showing a link between HIV antiretroviral treatment and meta-bolic disorders with guidelines that offer recommendations for assessing, monitoring, and treating the problem. -
FDA approves new rapid HIV test
The U.S. Department of Health and Human Services has announced that the U.S. Food and Drug Administration (FDA) has approved a new rapid HIV diagnostic test kit that provides results with 99.6% accuracy in as little as 20 minutes. -
Atazanavir found to help improve lipid profile
A new protease inhibitor (PI) called atazanavir was found to actually improve the lipid profile of HIV patients in a 48-week study presented at the 40th Annual Meeting of the Infectious Diseases Society of America (IDSA), held in Chicago. -
DAAT may work where DOT model fell short
While there are some similarities between HIV and tuberculosis (TB) treatments, its the differences in treatment regimens, duration, and end results that have made HIV clinicians and others somewhat hesitant to use the directly observed treatment (DOT) strategy, which has been so successful in treating TB, with HIV patients. -
Efavirenz effects worse than reported, study says
A study conducted at San Francisco General Hospital suggests a greater incidence rate of severe psychiatric illness resulting from HIV treatment with efavirenz than what has previously been reported. -
New guidance assists HIV drug development
The Food and Drug Administration (FDA) has issued new guidance intended to assist sponsors in the clinical development of drugs for the treatment of HIV infection. Specifically, it addresses the FDAs current thinking regarding designs of clinical trials that use HIV ribonucleic acid (RNA) measurements to support accelerated and traditional approvals of antiretroviral drug products.